Survival of patients with lung cancer and diabetes mellitus

  • Authors:
    • Koichi Kurishima
    • Hiroko Watanabe
    • Hiroichi Ishikawa
    • Hiroaki Satoh
    • Nobuyuki Hizawa
  • View Affiliations

  • Published online on: April 20, 2017     https://doi.org/10.3892/mco.2017.1224
  • Pages: 907-910
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diabetes mellitus (DM) and lung cancer are two highly globally prevalent diseases. The current study aimed to determine the prognostic significance of DM comorbidity in patients with lung cancer. All patients diagnosed at Tsukuba Medical Center Hospital and Mito Medical Center, (University of Tsukuba, Ibaraki, Japan) between April 1999 and March 2012 were followed up to 2015 and were retrospectively analyzed. DM was defined as a fasting plasma glucose (FPG) level ≥126 mg/dl, a non‑FPG level ≥200 mg/dl, or a hemoglobin (Hb) A1c level ≥6.5%. Additionally, patients taking medication for diabetes and those with a history of using such medications were also classified as having DM. During the study period, 1,798 patients with lung cancer were diagnosed. Within this cohort, 338 (18.8%) were classed as having lung cancer and DM. In univariate and multivariate analyses, smoking status, poorer performance status, small cell lung cancer pathology, metastatic disease and supportive care were the only unfavorable prognostic factors (all P=0.001). Additionally, multivariate analysis revealed that existing DM was an unfavorable disease‑modifying factor (P=0.03612). Therefore, DM comorbidity adversely affects lung cancer outcomes. To provide prolonged quality of survival, appropriate pre‑evaluation of lung cancer, as well as the patient's medical condition, including DM, is required.
View Figures
View References

Related Articles

Journal Cover

June-2017
Volume 6 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kurishima K, Watanabe H, Ishikawa H, Satoh H and Hizawa N: Survival of patients with lung cancer and diabetes mellitus. Mol Clin Oncol 6: 907-910, 2017
APA
Kurishima, K., Watanabe, H., Ishikawa, H., Satoh, H., & Hizawa, N. (2017). Survival of patients with lung cancer and diabetes mellitus. Molecular and Clinical Oncology, 6, 907-910. https://doi.org/10.3892/mco.2017.1224
MLA
Kurishima, K., Watanabe, H., Ishikawa, H., Satoh, H., Hizawa, N."Survival of patients with lung cancer and diabetes mellitus". Molecular and Clinical Oncology 6.6 (2017): 907-910.
Chicago
Kurishima, K., Watanabe, H., Ishikawa, H., Satoh, H., Hizawa, N."Survival of patients with lung cancer and diabetes mellitus". Molecular and Clinical Oncology 6, no. 6 (2017): 907-910. https://doi.org/10.3892/mco.2017.1224